Is Achaogen Incorporated (NASDAQ:AKAO)’s Fuel Running Low? Reports Show More Sellers

November 14, 2017 - By Dolores Ford

 Is Achaogen Incorporated (NASDAQ:AKAO)’s Fuel Running Low? Reports Show More Sellers

Investors sentiment increased to 2.38 in 2017 Q2. Its up 0.60, from 1.78 in 2017Q1. It is positive, as 11 investors sold Achaogen Inc shares while 18 reduced holdings. 35 funds opened positions while 34 raised stakes. 32.03 million shares or 27.26% more from 25.17 million shares in 2017Q1 were reported.
Td Asset Inc reported 0% of its portfolio in Achaogen Inc (NASDAQ:AKAO). 28,000 were accumulated by Hartwell J M Partnership. Ameriprise Finance has 0% invested in Achaogen Inc (NASDAQ:AKAO). Royal National Bank & Trust Of Canada holds 0% or 142 shares. Nicholas Inv Prns Ltd Partnership reported 0.28% in Achaogen Inc (NASDAQ:AKAO). Jpmorgan Chase & Communications holds 0% of its portfolio in Achaogen Inc (NASDAQ:AKAO) for 11,077 shares. Bank & Trust Of New York Mellon holds 0% of its portfolio in Achaogen Inc (NASDAQ:AKAO) for 191,670 shares. 98,818 were accumulated by Commercial Bank Of America De. Airain Ltd reported 31,507 shares. First Midwest Bankshares Division reported 20,388 shares. Sigma Planning Corporation holds 0.02% or 9,450 shares. Rhumbline Advisers accumulated 32,724 shares. Oppenheimer Asset Mgmt stated it has 7,654 shares or 0% of all its holdings. University Of Notre Dame Du Lac, a Indiana-based fund reported 103,868 shares. Schwab Charles holds 48,300 shares.

Since June 12, 2017, it had 0 buys, and 2 insider sales for $88,962 activity.

The stock of Achaogen Incorporated (NASDAQ:AKAO) registered an increase of 10.63% in short interest. AKAO’s total short interest was 8.82M shares in November as published by FINRA. Its up 10.63% from 7.97 million shares, reported previously. With 911,000 shares average volume, it will take short sellers 10 days to cover their AKAO’s short positions. The short interest to Achaogen Incorporated’s float is 46.18%.

About 185,699 shares traded. Achaogen Inc (NASDAQ:AKAO) has risen 757.99% since November 14, 2016 and is uptrending. It has outperformed by 741.29% the S&P500.

Achaogen, Inc. is a late-stage biopharmaceutical company. The company has market cap of $515.93 million. The Firm is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant gram-negative infections. It currently has negative earnings. The Firm is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).

Achaogen Inc (NASDAQ:AKAO) Ratings Coverage

Among 10 analysts covering Achaogen (NASDAQ:AKAO), 9 have Buy rating, 1 Sell and 0 Hold. Therefore 90% are positive. Achaogen had 20 analyst reports since March 16, 2016 according to SRatingsIntel. Cowen & Co downgraded Achaogen Inc (NASDAQ:AKAO) on Thursday, March 31 to “Market Perform” rating. The stock of Achaogen Inc (NASDAQ:AKAO) earned “Buy” rating by Needham on Friday, September 15. Stifel Nicolaus maintained Achaogen Inc (NASDAQ:AKAO) on Thursday, November 9 with “Buy” rating. Aegis Capital initiated the shares of AKAO in report on Wednesday, November 2 with “Buy” rating. The firm has “Outperform” rating by Wedbush given on Tuesday, June 14. Wedbush maintained the stock with “Outperform” rating in Wednesday, February 1 report. The firm has “Hold” rating by Needham given on Wednesday, March 16. As per Tuesday, December 13, the company rating was upgraded by Needham. The stock of Achaogen Inc (NASDAQ:AKAO) earned “Outperform” rating by Leerink Swann on Monday, October 9. The company was maintained on Tuesday, July 25 by Stifel Nicolaus.

More news for Achaogen Inc (NASDAQ:AKAO) were recently published by: Globenewswire.com, which released: “Achaogen to Present at the Stifel 2017 Healthcare Conference” on November 06, 2017. Seekingalpha.com‘s article titled: “Achaogen’s (AKAO) CEO Kenneth Hillan on Q3 2017 Results – Earnings Call Transcript” and published on November 09, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.